The role of copeptin in patients with subarachnoid haemorrage.

Objective: Subarachnoid haemorrhage is responsible to a great extend for the death rate of patients who are hospitalised in intensive care units (ICU) with haemorrhage. The early detection of its severity plays an important role for the resulting health of the patients. Neurohormone Copeptin is the C-end of pro-arginine vasopressin in plasma has been used as a prognostic marker in a number of various illnesses (acute myocardial infarction, heart and renal failure, acute dyspnoea, intracerebral and subarachnoid haemorrhage, ischaemic stroke, liver cirrhosis, acute pancreatitis).

Serum levels of fetuin-A in patients with coronary artery disease. Corellation with SPET myocardium scintigraphy.

Objective: Fetuin-A is an acidic glycoprotein produced in the liver, as an inhibitor for cysteine protease. Its gene is founded in chromosome 3 (3q27). It is involved in various physiological and pathological conditions.

Parathyroid adenoma detected with 99mTc-tetrofosmin dual-phase scintigraphy: a case report.

Background: Tc-sestamibi is the most frequently used radionuclide agent for the detection of parathyroid adenomas in the clinical setting. However, Tc-tetrofosmin is another such agent that may be used for this purpose. This case report presents the significance and practicality of 99mTc-tetrofosmin for the diagnosis of parathyroid adenomas with probable high p-glycoprotein levels.

External re-programmation by a new radionuclidic technique of electronic cerebrospinal fluid valve in case of hydrocephalus.

Hydrocephalus is defined as an abnormal enlargement of the ventricles of the brain due to an excessive accumulation of cerebrospinal fluid (CSF) because of a disturbance of its flow, absorption and/or secretion. The usual method of CSF diversion is a ventriculo-peritoneal shunt. Complications of implanted shunt systems include mechanical failure, shunt pathway obstruction, infection, foreign body (allergic) reaction to implants and CSF leakage along the implanted shunt pathway.